Thus, the combination of anti‐inflammatory and anti‐triglyceridemic activity with an ApoC3 inhibition strategy may prove superior to any prior therapy that has been trialed for PAD, and the effects of ApoC3 inhibition are likely to impact on coronary artery disease (CAD)‐related events in people with PAD and CAD as well. Here, APOC3 is linked to peripheral arterial disease.